BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them. OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)]. METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured. FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection. MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.

中文翻译：

---

评估不同的亚马逊利什曼原虫总抗原，以开发与Toll样受体3激动剂一起配制的预防皮肤利什曼病的第一代疫苗。

背景技术不幸的是，尚未开发出任何抗利什曼病的疫苗供人类使用。因此，基于利什曼原虫总抗原的疫苗可能是一种好的且经济的方法。而且获得这些抗原的方法也不同。然而，尚不清楚获得抗原的方法是否会影响它们引起的完整性和免疫应答。目的比较通过不同方法产生的亚马逊总乳杆菌抗原（TLA）产生的蛋白质谱和免疫应答，并分析由超声TLA（sTLA）和多肌苷酸配制的第一代疫苗的免疫应答和保护作用：聚胞苷酸[Poly（I：C）]。方法通过四种不同的方法获得TLA，并评估其完整性和免疫应答。最后，sTLA与Poly（I：C）并测量其保护性免疫应答。结果sTLA呈现保守的蛋白质谱并诱导了强烈的免疫反应。此外，聚（I：C）改善了sTLA产生的免疫反应。最后，sTLA + Poly（I：C）配方可部分防御亚马逊乳杆菌感染。主要结论蛋白质谱和免疫应答取决于用于获得抗原的方法。同样，sTLA + Poly（I：C）制剂可部分保护小鼠免受皮肤利什曼病的侵害。主要结论蛋白质谱和免疫应答取决于用于获得抗原的方法。同样，sTLA + Poly（I：C）制剂可部分保护小鼠免受皮肤利什曼病的侵害。主要结论蛋白质谱和免疫应答取决于用于获得抗原的方法。同样，sTLA + Poly（I：C）制剂可部分保护小鼠免受皮肤利什曼病的侵害。